Shopping Cart 0
Cart Subtotal
USD 0

Dementia-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Dementia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia-Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Dementia-Overview 6

Dementia-Therapeutics Development 7

Dementia-Therapeutics Assessment 20

Dementia-Companies Involved in Therapeutics Development 31

Dementia-Drug Profiles 57

Dementia-Dormant Projects 216

Dementia-Discontinued Products 220

Dementia-Product Development Milestones 221

Appendix 232


List Of Figure

List of Figures

Number of Products under Development for Dementia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Dementia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dementia-Pipeline by Accera Inc, H2 2017

Dementia-Pipeline by Acorda Therapeutics Inc, H2 2017

Dementia-Pipeline by Actinogen Medical Ltd, H2 2017

Dementia-Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by AgeneBio Inc, H2 2017

Dementia-Pipeline by Alector LLC, H2 2017

Dementia-Pipeline by Allergan Plc, H2 2017

Dementia-Pipeline by AlzProtect SAS, H2 2017

Dementia-Pipeline by Anavex Life Sciences Corp, H2 2017

Dementia-Pipeline by Asceneuron SA, H2 2017

Dementia-Pipeline by Axon Neuroscience SE, H2 2017

Dementia-Pipeline by Axovant Sciences Ltd, H2 2017

Dementia-Pipeline by BioArctic AB, H2 2017

Dementia-Pipeline by Biogen Inc, H2 2017

Dementia-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Dementia-Pipeline by Cortice Biosciences Inc, H2 2017

Dementia-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Echo Pharmaceuticals BV, H2 2017

Dementia-Pipeline by Eisai Co Ltd, H2 2017

Dementia-Pipeline by Eli Lilly and Company, H2 2017

Dementia-Pipeline by H. Lundbeck A/S, H2 2017

Dementia-Pipeline by Heptares Therapeutics Ltd, H2 2017

Dementia-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Immungenetics AG, H2 2017

Dementia-Pipeline by Intellect Neurosciences Inc, H2 2017

Dementia-Pipeline by Intra-Cellular Therapies Inc, H2 2017

Dementia-Pipeline by Ironwood Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by Johnson & Johnson, H2 2017

Dementia-Pipeline by M3 Biotechnology Inc, H2 2017

Dementia-Pipeline by MediPost Co Ltd, H2 2017

Dementia-Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by Neurimmune Holding AG, H2 2017

Dementia-Pipeline by Neuropore Therapies Inc, H2 2017

Dementia-Pipeline by Oryzon Genomics SA, H2 2017

Dementia-Pipeline by P2D Bioscience, H2 2017

Dementia-Pipeline by Pacific Northwest Biotechnology LLC, H2 2017

Dementia-Pipeline by Pharmasum Therapeutics AS, H2 2017

Dementia-Pipeline by Prana Biotechnology Ltd, H2 2017

Dementia-Pipeline by Sage Therapeutics Inc, H2 2017

Dementia-Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Stemedica Cell Technologies Inc, H2 2017

Dementia-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Dementia-Pipeline by Suven Life Sciences Ltd, H2 2017

Dementia-Pipeline by TauRx Therapeutics Ltd, H2 2017

Dementia-Pipeline by Theranexus SAS, H2 2017

Dementia-Pipeline by Vicore Pharma AB, H2 2017

Dementia-Pipeline by Voyager Therapeutics Inc, H2 2017

Dementia-Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017

Dementia-Dormant Projects, H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..1), H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..2), H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..3), H2 2017

Dementia-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment


Companies

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment

Dementia-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia-Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 11, 19, 1, 39, 10 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Dementia-Overview 6

Dementia-Therapeutics Development 7

Dementia-Therapeutics Assessment 20

Dementia-Companies Involved in Therapeutics Development 31

Dementia-Drug Profiles 57

Dementia-Dormant Projects 216

Dementia-Discontinued Products 220

Dementia-Product Development Milestones 221

Appendix 232


List Of Figure

List of Figures

Number of Products under Development for Dementia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Dementia, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Dementia-Pipeline by Accera Inc, H2 2017

Dementia-Pipeline by Acorda Therapeutics Inc, H2 2017

Dementia-Pipeline by Actinogen Medical Ltd, H2 2017

Dementia-Pipeline by Adamas Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by AgeneBio Inc, H2 2017

Dementia-Pipeline by Alector LLC, H2 2017

Dementia-Pipeline by Allergan Plc, H2 2017

Dementia-Pipeline by AlzProtect SAS, H2 2017

Dementia-Pipeline by Anavex Life Sciences Corp, H2 2017

Dementia-Pipeline by Asceneuron SA, H2 2017

Dementia-Pipeline by Axon Neuroscience SE, H2 2017

Dementia-Pipeline by Axovant Sciences Ltd, H2 2017

Dementia-Pipeline by BioArctic AB, H2 2017

Dementia-Pipeline by Biogen Inc, H2 2017

Dementia-Pipeline by Boehringer Ingelheim GmbH, H2 2017

Dementia-Pipeline by Cortice Biosciences Inc, H2 2017

Dementia-Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Echo Pharmaceuticals BV, H2 2017

Dementia-Pipeline by Eisai Co Ltd, H2 2017

Dementia-Pipeline by Eli Lilly and Company, H2 2017

Dementia-Pipeline by H. Lundbeck A/S, H2 2017

Dementia-Pipeline by Heptares Therapeutics Ltd, H2 2017

Dementia-Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Ildong Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Immungenetics AG, H2 2017

Dementia-Pipeline by Intellect Neurosciences Inc, H2 2017

Dementia-Pipeline by Intra-Cellular Therapies Inc, H2 2017

Dementia-Pipeline by Ironwood Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by Johnson & Johnson, H2 2017

Dementia-Pipeline by M3 Biotechnology Inc, H2 2017

Dementia-Pipeline by MediPost Co Ltd, H2 2017

Dementia-Pipeline by Neuraltus Pharmaceuticals Inc, H2 2017

Dementia-Pipeline by Neurimmune Holding AG, H2 2017

Dementia-Pipeline by Neuropore Therapies Inc, H2 2017

Dementia-Pipeline by Oryzon Genomics SA, H2 2017

Dementia-Pipeline by P2D Bioscience, H2 2017

Dementia-Pipeline by Pacific Northwest Biotechnology LLC, H2 2017

Dementia-Pipeline by Pharmasum Therapeutics AS, H2 2017

Dementia-Pipeline by Prana Biotechnology Ltd, H2 2017

Dementia-Pipeline by Sage Therapeutics Inc, H2 2017

Dementia-Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Stemedica Cell Technologies Inc, H2 2017

Dementia-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Dementia-Pipeline by Suven Life Sciences Ltd, H2 2017

Dementia-Pipeline by TauRx Therapeutics Ltd, H2 2017

Dementia-Pipeline by Theranexus SAS, H2 2017

Dementia-Pipeline by Vicore Pharma AB, H2 2017

Dementia-Pipeline by Voyager Therapeutics Inc, H2 2017

Dementia-Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017

Dementia-Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017

Dementia-Dormant Projects, H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..1), H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..2), H2 2017

Dementia-Dormant Projects, H2 2017 (Contd..3), H2 2017

Dementia-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment


Companies

Dementia Therapeutic Products under Development, Key Players in Dementia Therapeutics, Dementia Pipeline Overview, Dementia Pipeline, Dementia Pipeline Assessment